Abstract: 【Abstract】 The etiology and pathogenesis of chronic urticaria are complex. The main traditional treatment is oral antihistamines. With the progressive development in the biomedical field, targeted therapy has gradually become a new treatment option. Anti-immunoglobulin E monoclonal antibodies （omalizumab） can rapidly improve patients′ condition and enhance their quality of life during the treatment of chronic urticaria, and its clinical efficacy and safety have been gradually confirmed in clinical practice. This article summarizes and analyzes the current status of clinical diagnosis and treatment of chronic urticaria, discusses some common problems and corresponding strategies, and provides a reference for clinical management of these patients.

Key words: Urticaria, Mast cells, Immunoglobulin E, Histamine antagonists, Omalizumab